Avon Funds Breast Cancer Awareness Program for Orthodox Jewish Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

NEW YORK--The Avon Breast Health Access Fund has awarded a grant of $23,961 to Cancer Care for a program to increase awareness of the life-saving benefits of early breast cancer detection among low-income Orthodox Jewish women in New York City. Cancer Care is a nonprofit organization that provides free professional services to people with cancer and their families,

NEW YORK--The Avon Breast Health Access Fund has awarded a grantof $23,961 to Cancer Care for a program to increase awarenessof the life-saving benefits of early breast cancer detection amonglow-income Orthodox Jewish women in New York City. Cancer Careis a nonprofit organization that provides free professional servicesto people with cancer and their families,

The program will serve large enclaves of Orthodox Jewish womenwho, because of language, cultural beliefs, and socioeconomicreasons, receive inadequate health care. These women are not exposedto popular media that have long promoted breast health education.Moreover, because of modesty, the word breast is rarely used inthese communities.

The program will provide free educational seminars on the benefitsof early detection in the Orthodox Jewish communities, locatedprimarily in areas of Brooklyn. The seminars will be given inEnglish, Yiddish, Hebrew, and Russian, and, afterwards, the womenwill be given the opportunity to have a no- or low-cost mammogramand clinical exam.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content